BP is a rare autoimmune blistering skin disease that typically affects individuals older than 65 years. Currently, there is no cure for BP. The US/EU market size is currently estimated at 60,000 patients. The addressable global market for Bertilimumab in BP could reach $1.6 billion. http://www.immunepharma.com/product-portfolio/bertilimumab-draft/
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.